The cost to sequence a full human genome reached a critical milestone on Tuesday when Illumina announced its next-generation system will enable $1,000 tests. There are far-reaching implications for human health, but the possibilities extend beyond the doctor's office.
Direct-to-consumer genetic tests took a hit when the Food and Drug Administration told 23andMe to stop marketing its product. However, accepting the arrival of accessible genetic information could ignite growth opportunities for Myriad Genetics, Genomic Health, and Quest Diagnostics.
Contract Researchers have taken it on the chin following Parexel's (PRXL) lackluster quarterly results. But that view might be short sighted given drug makers are increasingly turning to CROs to usher drugs through trials.
Shares of Affymetrix have been on fire over the past year despite lacking any real fundamental fuel. Will this hot stock keep rising, or is it destined to crash and burn?
An unexpected court ruling crushes Sequenom. Is this bad news or the buying opportunity investors have been waiting for?
Diagnostics have been taking off around health care, from fast risers like Illumina to tried-and-true companies like Thermo-Fisher. Don't miss out on this health boom.
Which health-care stocks knocked the ball out of the park this week? These three companies scored double-digit gains.
An EU approval for an HIV therapy enhancing drug, mixed late-stage reviews for another big pharmaceutical company, and a rough week for two biotech standouts are this week's top stories.
How about a 50% gain in one week? That's the worst performance among these health-care high flyers.
The details behind Roche's deal with Pacific Biosciences of California.